{"public_id":"co_ee0d2eefe709f8b3b0f346e9cf24d220","status":"active","merged_into_public_id":null,"resolved_public_id":"co_ee0d2eefe709f8b3b0f346e9cf24d220","name":"pravastatin use","description":"Exposure to the statin pravastatin during the follow-up period.","aliases":["pravastatin therapy","pravastatin treatment"],"types":["drug exposure","intervention"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":24762552,"title":"Pravastatin Use and the Five-year Incidence of Cancer in Coronary Heart Disease Patients: from the Prevention of Coronary Sclerosis Study","citation_count":47,"url":"https://sah.borca.ai/papers/24762552"}],"claims":[{"public_id":"cl_343f9e860f5bd1fe9231526f758ca41c","text":"Observed-to-expected analysis found significantly elevated bladder cancer risk in all subjects and in pravastatin users.","corpus_id":24762552,"url":"https://sah.borca.ai/claims/cl_343f9e860f5bd1fe9231526f758ca41c"},{"public_id":"cl_8433a37f3f0159ec7f6dc9e834327783","text":"Five years of pravastatin use did not indicate an increase in overall cancer risk among coronary heart disease patients.","corpus_id":24762552,"url":"https://sah.borca.ai/claims/cl_8433a37f3f0159ec7f6dc9e834327783"},{"public_id":"cl_c0cbba752a00713606631f7c27497675","text":"Adjusted hazard ratio for cancer incidence with pravastatin use was 0.78, with a 95% confidence interval of 0.18 to 3.46.","corpus_id":24762552,"url":"https://sah.borca.ai/claims/cl_c0cbba752a00713606631f7c27497675"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_ee0d2eefe709f8b3b0f346e9cf24d220","url":"https://sah.borca.ai/concepts/co_ee0d2eefe709f8b3b0f346e9cf24d220"}